Analysis of the telomerase activity in renal cell carcinoma
| Project/Area Number |
08671811
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | KYOTO UNIVERSITY |
|---|
Principal Investigator |
TERACHI Toshiro Kyoto University, Urology, Assistant professor, 医学研究科, 講師 (50207487)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHICHIRI Yasumasa Kyoto University, Urology, Instructor, 医学研究科, 助手 (20263080)
OGAWA Osamu Kyoto University, Urology, Instructor, 医学研究科, 助手 (90260611)
KAKEHI Yoshiyuki Kyoto University, Urology, Assistant professor, 医学研究科, 講師 (20214273)
OKADA Yuusaku Kyoto University, Urology, Associate professor, 医学研究科, 助教授 (20127062)
YOSHIDA Osamu Kyoto University, Urology, professor, 医学研究科, 教授 (70025584)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1997: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1996: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | telomerase / renal cell carcinoma / chromophobe cell type / bladder cancer / chromophobe / RCC / TRAP / telomerase activity |
|---|
| Research Abstract |
In malignant tumors, telomerase reactivation plays an important role in the acquisition of cellular immortality. We examined the telomerase activity in 47 renal cell carcinomas (RCCs) and 9 RCC cell lines by telomericrepeat amplification protocol (TRAP) assay. Thirty-six (77%) of the 47 RCCs and all 9 RCC cell lines showed telomerase activity, whereasit was not detected inany of 30 normal kidneys. When the tumors were histopathologically classified, only one of the 6 chromophobe cell carcinomas was telomerase-positive. This frequency was quite different from those in the other subtypes of 24 (93%) of 26 clear cell RCCs, 6 (67%) of 9 papillary RCC,and 3 (75%) of 4 granular cell RCCs. The mechanism for preventing the telomere shortening may differ according to the RCC subtypes. Alternatively, telomerase-negative tumors may not yet have reached the immortal stage when they progress to clinical cancer. The telomerase activity status may contribute to the biological potential and the prognosis of certain tumors.
We also examined telomerase activity in tumor specimens from a cohort of patients with bladder cancer and determined whether telomerase could be detected in exfoliated cancer cells present in urine from these patients. Telomerase activity can be detected in exfoliated cells in urine from patients with bladder cancer, and measurement of this activity appears to be more sensitive in detecting the presence of cancer than standard urine cytologic examination
|
Report
(3 results)
Research Products
(6 results)
